---
area: society-systems
category: general
companies_orgs:
- Health Canada
- The Brain Institute
- McGill University
date: '2025-11-05'
draft: true
guest: ''
insight: ''
layout: post.njk
products_models:
- Lecanemab
- Leqembi
project:
- systems-thinking
series: ''
source: https://www.youtube.com/watch?v=a5J5F5HTQNc
speaker: TVO Today
status: evergreen
summary: 加拿大批准了一种名为Lecanemab（商品名Leqembi）的阿尔茨海默病新药，引发了广泛关注。该药物通过清除大脑中的淀粉样β蛋白来减缓认知衰退，但并非治愈手段，且存在脑肿胀和微出血等副作用。本文深入探讨了Lecanemab的作用机制、适用人群、高昂费用及其对加拿大医疗系统的潜在影响，并讨论了痴呆症诊断和治疗的未来展望，强调了及时诊断和多模式治疗的重要性。
tags:
- code
- cognitive
- health
- healthcare-system
- society
title: 阿尔茨海默病新药Lecanemab：能否为加拿大医疗系统带来变革？
---

### 引言：阿尔茨海默病的挑战与Lecanemab的出现

目前，加拿大约有77万人患有痴呆症，预计到2031年这一数字将上升至93.7万人。阿尔茨海默病是痴呆症最常见的病因，目前尚无治愈方法。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Almost 770,000 Canadians live with dementia today. That number is projected to rise to 937,000 by 2031. Alzheimer's disease is the most common cause of dementia, and currently there's no cure.</p>
</details>

由加拿大卫生部（Health Canada）最近批准的药物**Lecanemab**（Lecanemab: 一种新型阿尔茨海默病药物），能否为患者和我们的医疗系统带来真正的改变？为了了解更多，我们采访了神经科学家Saskia Sivanathan，她是“大脑研究所”（The Brain Institute）的创始人兼首席执行官，同时也是麦吉尔大学（McGill University）家庭医学系的附属教授。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Could lecanemab, a drug recently okayed by Health Canada, make a real difference for patients and for our health care system? For more, I talked to neuroscientist Saskia Sivanathan, founder and CEO of the Brain Institute and affiliate professor in the Department of Family Medicine at McGill University.</p>
</details>

Saskia Sivanathan女士，欢迎来到节目。您好吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Saskia, welcome to the program. How are you doing?</p>
</details>

您好，谢谢邀请。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Good. Thanks for having me.</p>
</details>

我们正在讨论Lecanemab。我们需要了解它哪些方面？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, we are talking about Lecanemab. What do we need to know about it?</p>
</details>

### Lecanemab的工作原理及其影响

好的，Lecanemab 101。它的商品名是**Leqembi**（Leqembi: Lecanemab的商品名）。这种新药因多种原因引起了广泛关注。它是首个真正针对阿尔茨海默病潜在病理机制的药物。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Okay, so Lecanemab 101. So the brand name is Leqembi. And there's a lot of excitement around this new drug for a range of reasons. It's the first of its kind that really starts to get at the underlying pathology of Alzheimer's disease specifically.</p>
</details>

Lecanemab的作用方式是，它与一种在阿尔茨海默病患者大脑中积累的特定蛋白质结合，这种蛋白质叫做**淀粉样β蛋白**（Amyloid Beta: 阿尔茨海默病患者大脑中积累的一种蛋白质）。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So the way Lecanemab works is it binds to a certain protein that accumulates in the brains of people who have Alzheimer's disease, and that protein is called amyloid beta, okay.</p>
</details>

在大多数阿尔茨海默病患者的大脑中，淀粉样β蛋白团块形成的斑块是该疾病的标志之一。人们认为正是这些斑块阻止了脑细胞之间的沟通。

<details>
<summary>View/Hide Original English</summary
<p class="english-text">And one of the hallmarks of Alzheimer's disease in most of the brains of people who have Alzheimer's disease. Are these plaques made up of that amyloid protein that clumps together. And it's thought to that's what prevents the brain cells from communicating with each other.</p>
</details>

所以，Lecanemab的作用是进入大脑，与这种蛋白质结合并将其清除。他们观察到的是认知衰退的速度减慢，这是阿尔茨海默病的主要症状之一。它能将衰退速度减缓数月至一年。这就是Lecanemab的工作原理。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So the way Lecanemab works is it goes in, binds to that protein and removes it from the brain. And what they see is that there's a slowing of the cognitive decline, which is one of the main symptoms of Alzheimer's disease. It slows it by several months to up to a year. So that's that's how Lecanemab works.</p>
</details>

### Lecanemab的给药方式、适用条件与副作用

它是以药丸形式服用吗？是注射吗？它的给药方式是怎样的？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Is it are we using it as a pill? Is it an injection? How does it work in that way.</p>
</details>

所以，它不是药丸。它需要每周进行几次静脉输注。它有特定的治疗方案。这意味着，如果你符合条件，你可能需要去特定的临床地点接受治疗。在使用过程中，还需要通过**MRI**（Magnetic Resonance Imaging: 磁共振成像）进行非常仔细的监测。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So it's not a pill okay. It is going to require IV infusion a couple of times a week. There's a there's a protocol for it. And so it means that you'd have to probably go into a specific clinical site if you're eligible for it to get it as well. You need to be monitored very carefully using MRI imaging.</p>
</details>

那为什么要这样呢？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So why is that?</p>
</details>

哦，原因很好。首先，要符合Lecanemab的条件，你必须被临床诊断为早期阿尔茨海默病或轻度认知障碍。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Oh good reason. So first of all, in order to be eligible for Lecanemab, you have to have a clinical diagnosis of early stage Alzheimer's or mild cognitive impairment.</p>
</details>

我在这里退一步解释一下。痴呆症是一个更广泛的术语，但它实际上是一个涵盖100多种不同疾病的总称，其中阿尔茨海默病是最常见的，但还有许多其他类型，如帕金森病相关性痴呆、额颞叶痴呆等。但这种药物仅适用于阿尔茨海默病，而且是早期阿尔茨海默病。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So I'll take a step back here. Zoom back a bit because dementia is the term that's being used more broadly, but that's really an umbrella term for over 100 different types of diseases, Alzheimer being the most common, but there are many others Parkinson's related, dementia, frontal, temporal, all of that. But this is only for Alzheimer's disease and early stage Alzheimer's.</p>
</details>

你必须在大脑中存在淀粉样β蛋白病理。这就是为什么需要通过影像学检查来确认你是否存在这种病理。此外，他们还需要监测正在使用Lecanemab的患者，因为该药物存在副作用，需要进行此类监测。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And you have to have amyloid beta pathology in the brain. So that's why the imaging through the imaging, they can confirm if you have that pathology. And then they do need to monitor people who are on lecanemab, because there are side effects to it that require that kind of monitoring.</p>
</details>

我想确保我们清楚一点：它不是治愈方法，也不能逆转阿尔茨海默病。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I want to make sure we're clear here, not a cure. Cannot reverse Alzheimer's disease.</p>
</details>

完全正确。它绝对不是治愈方法，也不能逆转阿尔茨海默病，但它能减缓疾病的进展。它是首类处理阿尔茨海默病潜在病理的药物，而目前市场上的其他药物更多是针对阿尔茨海默病的症状管理。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Exactly. Absolutely is not a cure. Does not reverse Alzheimer's, but slows the progression. And it's the first class of drugs that is dealing with the underlying pathology of Alzheimer's, whereas all the other drugs that are currently on the market are more about the symptomatic management of Alzheimer's.</p>
</details>

这就是为什么人们如此乐观的原因吗？还是有其他原因？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Is that why there is so much optimism, or is there.</p>
</details>

还有更多原因吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">More to it?</p>
</details>

还有更多原因。我认为还有更多原因。我来稍微深入解释一下。我认为第一个原因是，阿尔茨海默病或广义痴呆症已经十多年没有新药上市了。所以，仅凭这一点就是一个很大的原因，对吧？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">There's more to it. I think there's more to it. So I'll get into it a little bit. I think the first is it's been over ten years since there's been any drug on the market for Alzheimer or dementia broadly. So I mean, that alone is a big reason, right?</p>
</details>

而且，许多备受瞩目的临床试验都失败了，投入了大量资金用于阿尔茨海默病的研究。所以，再次强调，拥有这类首创药物意义重大。第二个原因是，这是首类获得市场批准的药物，再次针对潜在病因，这是其他药物没有做到的。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And there have been a lot of high profile clinical trials that failed with a lot of money that went into it for Alzheimer's. So again, to have this first class of drug, big deal. The second is, is this is the first class that has received market approval to again get at the underlying cause, which others didn't.</p>
</details>

但第三个争议点是副作用。它确实有一种叫做**ARIA**（Amyloid-Related Imaging Abnormalities: 淀粉样蛋白相关影像学异常）的副作用。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">But the third for the controversy is the side effect. So it does have a side effect called Aria which is amyloid related imaging abnormalities.</p>
</details>

请为我们拼写一下。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Spell that for us.</p>
</details>

ARIA。ARIA是一个缩写词。我喜欢缩写词。基本上，它的意思是，一些接受Lecanemab治疗的患者会出现脑肿胀和微出血。这就是为什么需要通过MRI进行非常仔细监测的另一个原因。但我们知道，MRI基础设施和可及性可能很困难。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Aria. Aria it's an acronym Love acronyms. And basically what it means is that some of the people who do receive Lecanemab have brain swelling and microbleeds. So this is the other reason why they need to be monitored very carefully through MRIs. But as we know, MRI infrastructure and access can be tough.</p>
</details>

好的，资格。这种药上市后，谁能得到它？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Okay, eligibility. Who gets this when it's on the market okay.</p>
</details>

所以，市场批准非常具体。它适用于成年人。我之所以特别指出这一点，是因为存在儿童相关的痴呆症。这种药只适用于成年人。它适用于轻度认知障碍，这是痴呆症的早期阶段，可能导致阿尔茨海默病。但并非每个人都会发展成阿尔茨海默病。它也只适用于早期阿尔茨海默病。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So market approval is very specific. It's for adults. And the reason I specify that is because there are childhood related dementias. This is for adults only. It's for mild cognitive impairment which is an earlier stage of dementia that can lead to Alzheimer's. But not everyone does develop it. And it's for early stage Alzheimer's only.</p>
</details>

这一点也非常重要，因为通常很难获得诊断。是的，我们稍后可以深入讨论这一点。但需要记住的另一点是，你大脑中必须存在淀粉样蛋白病理，因此需要进行影像学检查。第三点是，如果人们拥有一种名为**ApoE e4**（Apolipoprotein E e4: 一种与阿尔茨海默病风险相关的基因变体）的基因，特别是该基因的e4变体，这会使患阿尔茨海默病的风险更高。如果他们同时拥有这两种变体，则不符合用药资格。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Now that is very important as well, because it's often difficult to get the diagnosis. Yes, and we can get into that a bit later. But the other piece to remember is, is that you have to have amyloid pathology in the brain, hence the imaging. And the third is, is that people who have a gene called the Apoe and specifically the Apoe e4, it's a variant of that gene, puts you at a higher risk of developing Alzheimer's. So they are ineligible for the drug if they have both of the variants.</p>
</details>

很有趣。好的。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Very interesting. Okay.</p>
</details>

是的。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah.</p>
</details>

### Lecanemab的审批过程、成本与可及性

我想谈谈。你知道，人们对此充满乐观和兴奋。但你也提到了副作用，此外还有相关的成本。我们知道成本是多少吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I want to talk. You know, there's a lot of optimism, a lot of excitement around this. But there is also you mentioned the side effects, but there's also a cost associated. Do we know what the cost is?</p>
</details>

我们还不知道成本。加拿大实际上是第50个批准该药物的国家。所以我们花了一些时间。为什么？有很多不同的原因。审批过程非常严格，我认为加拿大喜欢拥有自己的数据，不一定根据其他国家的批准情况来做决定。

<details>
<summary>View/Hide Original English</summary
<p class="english-text">We don't we don't know the cost yet. And Canada is actually the 50th country to approve. So we took our time. Why? A lot of different reasons. The process is very rigorous, and I think Canada likes to have its own data, doesn't necessarily make decisions based on how other countries are approving.</p>
</details>

它在美国、日本等国家都获得了批准。然而，重要的是，由于这些市场已经批准并可以使用该药物，你现在拥有了更多的真实世界数据。你知道这种药物在这些社区中的表现如何，并且拥有更长的纵向数据。所以，这对于某些定价决策来说很重要。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">It was approved in the US, in countries like Japan, etc. So the the important piece about that though, is that you have more real world data because they've been approved and accessible in those markets. You now know how that drug is doing in those communities and you have more longitudinal data. So that's important for how some of the decision making might be made price-wise.</p>
</details>

在美国，仅药物本身的年费约为27,000美元。这还不包括静脉输注和MRI的潜在费用。现在，他们有私人医疗系统。我们是公共医疗系统。所以，还有很多这些方面需要考虑。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">In the US, it's priced at about 27,000 USD annually only for the drug. Okay. It's not including the cost potentially of IV infusions and MRIs. Now, they do have a private system. Ours is a public system. So there's a lot of those pieces to think through as well.</p>
</details>

那么，我们来谈谈这个问题。它会由公共资金资助吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, let's talk about it. Yeah. Will it be publicly funded.</p>
</details>

我们不知道，因为这取决于每个省份愿意资助多少，以及私人保险公司是否会覆盖。但这个价格问题已经提出来了一点，对吧？我的意思是，如果它是27,000美元，你知道，那对加拿大元意味着什么？但我经常会想到其他一些重大疾病，比如癌症、中风。对吧？你知道，对于其中一些药物，其价格与这些治疗方案相当，甚至更高。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We don't know because that is a decision up to each province around how much they're willing to fund whether private insurers will cover it or not. But this price piece has come up a bit, right? I mean, if it's 27,000 USD, you know, what will that mean for Canadian dollars? But I often do think about other large conditions like cancer, stroke. Right. And you know, for some of those those drugs, it's comparable if not more for those treatment options.</p>
</details>

所以，我认为当你考虑像阿尔茨海默病这样的疾病时，你正在谈论一种几乎没有其他真正好的治疗选择的疾病。平均而言，患者会带着这种疾病生活八年。疾病的进展意味着语言丧失、认知丧失、功能丧失，直到最终这个人无法再照顾自己。对吧？他们需要24/7的护理。这在很多方面都是一种毁灭性的疾病。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So I think when you're thinking about a disease like Alzheimer's disease, you're talking about a disease that has had really no other really good treatment options. You're living for on average eight years with the disease. And the progression means that it's language loss. It's cognitive loss, functional loss, until eventually this person can no longer take care of themselves. Right. They need 24 over seven care. It's a it's a devastating disease in many ways.</p>
</details>

那么，如果它不是公共资助的，那些需要它的人，正如你所说，这种疾病是多么致命，他们将如何获得它？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, if it's not publicly funded, how do people who do need it, as you mentioned, how deadly it is, how will they get it?</p>
</details>

如果他们有私人保险，并且私人保险公司愿意覆盖，那很可能是通过私人保险获得。所以，关于这种药物，在这方面有很多方面需要考虑。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">It will likely be private insurance if they have private insurance at that point and if private insurers will cover it. So there's a lot of pieces to consider with the drug on that front.</p>
</details>

好的。目前有超过75万加拿大人患有痴呆症。我们如何确保当这种药物上市时，加拿大能够获得，你知道，他们能够在需要时获得它？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">All right. There are over three quarters of a million Canadians currently living with dementia. How do we ensure that when this drug does hit the market, Canada is accessible, has, you know, they have the ability to get it when they need it?</p>
</details>

是的。我的意思是，它的资格标准非常严格。所以这可能意味着只有一小部分人，可能不到10%的人，有资格使用这种药物。但另一个关键点是及时获得诊断。我们之前简要提到了这一点。平均而言，诊断痴呆症需要大约两年时间。这是一个很长的时间。这意味着那个窗口可能会关闭。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah. Well, I mean, it is very tight eligibility. So what that likely means is only a small percentage of people will even be eligible for the drug, likely under 10%. But the other piece to this is being diagnosed in a timely way. So we touched on that briefly. Right. On average, it's taking about two years to get a diagnosis of dementia. That's a long time. And that means that that window might close.</p>
</details>

为了真正支持这种可及性，我们需要协调和更好的临床路径。而且你需要更多的治疗选择。这只是第一类药物。希望还有一整条研发管线正在推进。但我们也知道，还需要有其他可用于痴呆症的治疗选择。而我们的医疗系统根本没有这些。真的没有协调。一旦你得到诊断，你就会被置之不理，自己去弄清楚下一步该怎么做。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And in order to really support that kind of accessibility, we need coordination and better clinical pathways. And you need more treatment options. This is just a first class of drugs. There's a whole pipeline that hopefully will be coming through. But we also know there are other treatment options that need to be available for dementia. And we just don't have that in our health system at all. There's really no coordination. You're kind of left on your own once you get the diagnosis to figure out what to do next.</p>
</details>

### 痴呆症治疗的未来展望

好的。那么，除了Lecanemab之外，还有哪些新的治疗方法正在开发中或在研发管线中，让您抱有希望？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">All right. Well, let's talk about that. Aside from Lecanemab, what are some other new treatments that are out there or that are in that pipeline that are giving you some hope?</p>
</details>

所以，有三类。第一类是药物治疗选择。有一整条研发管线，针对的是另一种叫做**tau蛋白**（tau protein: 另一种与阿尔茨海默病相关的蛋白质）的蛋白质，这种蛋白质也存在于大脑中，并考虑了神经炎症。所以，不同类型的标志物再次针对阿尔茨海默病以及更广泛的痴呆症的潜在病理。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So there are kind of three things. There's the drug treatment options. There's a whole pipeline, things that are targeting a different type of protein called tau that's also in the brain thinking about neuroinflammation. So different types of markers that are getting again at that underlying pathology of Alzheimer's and then broader dementia. So there's I think a lot of hope because a lot of those will read out, those clinical trials will read out over the next couple of years.</p>
</details>

所以我认为有很多希望，因为许多这些临床试验的结果将在未来几年内公布。第二类是基于血液的**生物标志物**（Biomarkers: 用于诊断疾病或评估治疗效果的生物指标）。这些离上市更近了。它们的作用是，通过血液测试就能判断某人是否患有阿尔茨海默病或其他形式的痴呆症。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">The second are blood based biomarkers. So these are much closer to getting to the market. And what they do is it means it's a blood test to be able to see if someone has Alzheimer's or other forms of dementia.</p>
</details>

再次强调，这很重要，因为现在主要通过认知测试来诊断，这非常困难。特别是如果有人说不同的语言，或者存在认知评估中未考虑到的文化细微差别。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Again, that's important because right now it's just a cognitive test, mainly for being able to diagnose someone, which is really difficult. Especially someone speaks a different language. Cultural nuances that don't get considered in a cognitive assessment.</p>
</details>

但另一部分是康复治疗，我们现在知道这非常重要，并且有助于减缓功能衰退。还有多模式生活方式选择，比如运动、饮食和认知疗法，这些结合起来也能减缓认知衰退。而我们现在并没有向痴呆症患者提供这些。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">But the other piece is, are rehabilitation therapy, which we now know is really important and supports slowing the functional decline and then multimodal lifestyle options. So exercise, diet and cognitive therapy, which in combination can also slow cognitive decline. And we don't offer any of those right now to people living with dementia.</p>
</details>

Saskia，我们就谈到这里吧。非常感谢您。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Saskia, we're going to leave it there. Thank you so much.</p>
</details>

我的荣幸。谢谢邀请。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">My pleasure. Thanks for having me.</p>
</details>